stockportfolio.pro
Upstream Bio, Inc. (UPB)
Healthcare · Biotechnology · NasdaqGS
Upstream Bio, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.21M | $2.38M | $2.37M | $2.85M |
| Gross profit | — | — | — | — |
| Net income | $-23.87M | $-20.54M | $-62.81M | $-143.44M |
| Net margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
Source: Upstream Bio, Inc. SEC filings (10-K).
Explore 4 years of Upstream Bio, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track UPB in your portfolio →
Upstream Bio, Inc. financial history by metric
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Upstream Bio, Inc. — frequently asked questions
What is Upstream Bio, Inc.'s revenue?
Upstream Bio, Inc. (UPB) reported revenue of $2.85M for fiscal year 2025, up 20.4% from the prior year, according to its SEC filings.
Is Upstream Bio, Inc. profitable?
No — UPB reported a net loss of $-143.44M in fiscal 2025.
What is UPB's P/E ratio?
Upstream Bio, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Upstream Bio, Inc. growing?
UPB's revenue grew at roughly 33.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Upstream Bio, Inc. have?
As of fiscal year 2025, UPB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Upstream Bio, Inc.'s market cap?
Upstream Bio, Inc. (UPB) has a market capitalization of about $343.93M, based on the latest data in our nightly-refreshed cache.
When does Upstream Bio, Inc.'s fiscal year end?
UPB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Upstream Bio, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.